Market Performance
Indegene’s share price surged 3% on Thursday, recovering from the previous day’s losses. The stock reached an intraday high of ₹609.80, which is still 20% below its 52-week peak of ₹736.30.
This rebound followed a 4% drop on Wednesday after Carlyle Group sold its entire 10.2% stake in the company.
Key Stakeholders’ Transactions
Several prominent investors acquired shares in bulk, boosting market sentiment:
- PI Opportunities (Azim Premji-backed) invested ₹100 Crore
- Societe Generale (France) bought a 0.21% stake for ₹111 Crore
- Capital Group’s Small Cap World Fund pumped in ₹108 Crore
- Eastbridge Capital acquired a 0.24% stake for ₹128 Crore
Collectively, these investors picked up 1.06 Crore shares (4.42% stake) for ₹627 Crore at ₹591–591.48 per share.
Carlyle Group’s Exit Strategy
Carlyle Group, which initially invested ₹917 Crore in 2021 at ₹201 per share, exited in phases:
- IPO (May 2024): Sold shares at ₹452
- December 2024: Offloaded stake at ₹618
- June 2025: Final exit at ₹591 per share
The private equity firm secured strong returns across different market conditions.
Company Overview
Indegene, a global healthcare solutions provider, went public in May 2024. Its expansion and IPO attracted significant investor interest before Carlyle’s exit.
Summary
- Indegene’s share price rose 3% after major investors bought stakes.
- ₹627 Crore worth of shares exchanged hands in block deals.
- Carlyle Group exited completely, booking profits after a 4-year investment.
The stock remains 20% below its 52-week high.
